GlassScriptPhysician profile
Carol F Actor
NPI 1851444269
$385.26
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $11.39 · 2021: $13.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $71.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $59.56 | 2019 | |
| Kaleo, INC. | $58.30 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $57.10 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $31.50 | 2019 | |
| Pfizer INC. | $24.38 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $23.65 | 2019-2020 | |
| Grifols USA, LLC | $23.12 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.85 | 2019 | |
| Alk-Abello, INC | $14.18 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Actor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.